Movement Disorders

Experts debate the challenges of carbidopa/levodopa, and the relation between levodopa and the gut.

Here's what is coming soon to NeurologyLive.

Previously, many promising treatments for PD have ultimately resulted in untenable adverse effects or in failure, but the evolving area of protein folding offers an opportunity to slow or reverse the neurodegenerative process.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 29, 2021.

Panelists describe the motor and non-motor symptoms of Parkinson’s disease, linking symptoms to OFF episodes, and how to educate patients.

A discussion on how patients are evaluated for OFF episodes, by expert neurologists.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 22, 2021.

The trial provided Class IV evidence that VY-AADC01 and the associated surgical delivery procedure were well-tolerated in patients aged 40 to 70 years with moderately advanced Parkinson disease.

The duo from MedStar Georgetown University Hospital detailed the need for education on Parkinson disease and movement disorder therapies, and the CME activities they’ve developed with the PMD Alliance to address those needs. [WATCH TIME: 5 minutes]

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of utilizing palliative care principles in the regular care of Parkinson disease. [WATCH TIME: 7 minutes]

The PMD Alliance has developed a group of 6 on-demand CME events and live panel discussions, in partnership with MedStar Georgetown University Hospital, taking place on October 23-24, 2021, developed and presented by Yasar Torres-Yaghi, MD , and Fernando Pagan, MD.

Physicians explain expected versus unexpected OFF episodes and the use of symptom diaries in managing Parkinson’s disease.

Key opinion leaders provide insight on how OFF episodes affect patients’ quality of life.

Here's what is coming soon to NeurologyLive.

In light of the RISE-PD study data, the research chair for Parkinson’s Disease and Movement Disorders at University of Cincinnati Health offered insight into IPX-203 in Parkinson disease. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 15, 2021.

The research chair for Parkinson’s Disease and Movement Disorders at University of Cincinnati Health discussed the therapy’s results in a study of its effect on Parkinson disease. [WATCH TIME: 6 minutes]

In the cohort of 14 patients with preoperative impulsive and compulsive behavior burden, 6 patients demonstrated clinically relevant improvement on QUIP-RS, while 1 worsened and 7 remained stable.

Expert neurologists discuss why OFF episodes happen and how soon they occur after starting levodopa.

Panelists have a conversation on the definition of OFF episodes in relation to Parkinson’s disease and how common OFF episodes are for patients.

Gennero Pagano, MD, MSc, PhD, expert medical director, Roche, provided thoughts on the investigational agent prasinezumab, overall Parkinson drug development, and MDS Virtual Congress.

Here's what is coming soon to NeurologyLive.

The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 8, 2021.

Patients treated in the 10- and 20-mg once daily groups showed statistically significant improvements in UPDRS parts II, III, IV, and in total MDS-UPDRS scores compared with baseline.

The research chair for Parkinson’s Disease and Movement Disorders at University of Cincinnati Health spoke to the current state of treatment for Parkinson disease. [WATCH TIME: 2 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

The expert medical director at Roche provided context on recently published data, which showed prasinezumab’s positive impact in delaying motor progression in patients with Parkinson disease.